Literature DB >> 11840258

Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation.

N Schaap1, A Schattenberg, E Mensink, F Preijers, M Hillegers, R Knops, A Pennings, J Boezeman, A Geurts van Kessel, B de Pauw, T de Witte.   

Abstract

Using red cell phenotyping (RCP) and/or cytogenetics (CYT) we identified 19 patients with persisting mixed chimerism (MC) among 231 patients transplanted with partially T cell-depleted stem cell grafts from HLA-identical siblings. Persisting MC is defined as MC for more than 2 years in patients without any evidence of relapse. Median leukemia-free survival in these patients was 150 (range, 50-218) months. Diagnoses were ALL (n= 10); AML (n = 2); CML (n = 2); NHL (n = 2); MDS (n= 1); MM (n = 1) and SAA (n = 1). Purpose of this study was the long-term follow-up of MC and definition of patterns of chimerism in the various subsets of PBMCs and granulocytes. Using a PCR-STR technique CD3(+)/CD4(+) (T4 lymphocytes), CD3(+)/CD8(+) (T8 lymphocytes), CD45(+)/CD19(+) (B lymphocytes), CD45(+)/CD14(+) (monocytes), CD45(+)/CD15(+) (granulocytes) and CD3(-)/CD56(+) (NK-cells) were analyzed. The majority of patients with persisting MC were conditioned with a less intensive conditioning regimen and had little GVHD. Sequential monitoring of the chimerism resulted in a group of patients (n = 7) with very slow transient mixed chimerism that resulted in complete DC after median 7 years. Another nine patients had a relatively high percentage of persisting autologous cells for a median of 12 years and in three patients we observed a stable low percentage of autologous cells. Only two out of 19 patients (AML-CR1, CML-CP1) relapsed during follow-up. Both patients had a relatively high percentage of autologous cells. Chimerism in granulocytes and PBMC subsets was analyzed at a median of 8 years after SCT in nine patients. In five patients mixed chimerism simultaneously detected by RCP and CYT was associated with MC in all subsets. Within each individual patient the percentages of donor and recipient cells were very different between the different subsets. Two CML-CP1 patients were mixed chimera in only two subsets and in one patient these subsets represented pending relapse. In another two patients mixed chimerism with a very low number of autologous red cells was not found in the PBMCs because of the different sensitivity level of the RCP and the PCR-STR technique. We conclude that in patients with persisting mixed chimerism after partially T cell-depleted SCT a remarkable number of patients had lymphoid malignancies, the majority of the patients were conditioned with less intensive conditioning regimens and the mixed chimerism was not correlated with relapse. Chimerism in granulocytes and PBMC subsets did show great intra-individual differences in the subsets and these data correlated well with RCP and CYT data with the exception of the NK cells.

Entities:  

Mesh:

Year:  2002        PMID: 11840258     DOI: 10.1038/sj.leu.2402343

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  12 in total

1.  Quantitative chimerism in CD3-negative mononuclear cells predicts prognosis in acute myeloid leukemia patients after hematopoietic stem cell transplantation.

Authors:  Anne Bouvier; Jérémie Riou; Sylvain Thépot; Aurélien Sutra Del Galy; Sylvie François; Aline Schmidt; Corentin Orvain; Marie-Hélène Estienne; Alban Villate; Damien Luque Paz; Laurane Cottin; Bénédicte Ribourtout; Annaëlle Beucher; Yves Delneste; Norbert Ifrah; Valérie Ugo; Mathilde Hunault-Berger; Odile Blanchet
Journal:  Leukemia       Date:  2019-11-25       Impact factor: 11.528

Review 2.  Hematologic aspects of myeloablative therapy and bone marrow transplantation.

Authors:  Roger S Riley; Michael Idowu; Alden Chesney; Shawn Zhao; John McCarty; Lawrence S Lamb; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

3.  Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  Hans C Lee; Rima M Saliba; Gabriela Rondon; Julianne Chen; Yasmeen Charafeddine; L Jeffrey Medeiros; Gheath Alatrash; Borje S Andersson; Uday Popat; Partow Kebriaei; Stefan Ciurea; Betul Oran; Elizabeth Shpall; Richard Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-14       Impact factor: 5.742

Review 4.  The transplantation of hematopoietic stem cells after non-myeloablative conditioning: a cellular therapeutic approach to hematologic and genetic diseases.

Authors:  Michael Maris; Rainer Storb
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

5.  Lineage-specific chimerism analysis in nucleated cells, T cells and natural killer cells after myeloablative allogeneic hematopoietic stem cell transplantation.

Authors:  Ri-Young Goh; Sung-Hyun Kim; Jin-Yeong Han
Journal:  Korean J Hematol       Date:  2011-03-15

6.  Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?

Authors:  Arwen Stikvoort; Mikael Sundin; Mehmet Uzunel; Jens Gertow; Berit Sundberg; Marie Schaffer; Jonas Mattsson; Michael Uhlin
Journal:  PLoS One       Date:  2016-05-06       Impact factor: 3.240

7.  Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy.

Authors:  Shatha Farhan; Michael Bazydlo; Klodiana Neme; Nancy Mikulandric; Edward Peres; Nalini Janakiraman
Journal:  Adv Hematol       Date:  2017-11-08

8.  Automated detection of residual cells after sex-mismatched stem-cell transplantation - evidence for presence of disease-marker negative residual cells.

Authors:  Jörn Erlecke; Isabell Hartmann; Martin Hoffmann; Torsten Kroll; Heike Starke; Anita Heller; Alexander Gloria; Herbert G Sayer; Tilman Johannes; Uwe Claussen; Thomas Liehr; Ivan F Loncarevic
Journal:  Mol Cytogenet       Date:  2009-05-29       Impact factor: 2.009

9.  Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies.

Authors:  Emmanuel Levrat; Eddy Roosnek; Stavroula Masouridi; Bilal Mohty; Marc Ansari; Jean Villard; Jakob R Passweg; Yves Chalandon
Journal:  Bone Marrow Res       Date:  2015-11-10

10.  Simultaneous Monitoring of Mutation and Chimerism Using Next-Generation Sequencing in Myelodysplastic Syndrome.

Authors:  Jong-Mi Lee; Yoo-Jin Kim; Sung-Soo Park; Eunhee Han; Myungshin Kim; Yonggoo Kim
Journal:  J Clin Med       Date:  2019-11-28       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.